QNRX שווי כולל של נכסי החברה Quoin Pharma

The price action of Quoin Pharmaceuticals (QNRX) securities on the GURU.Markets platform, where total assets amount to 10.44, illustrates the operations of this developer of skin pathology therapies. The business relies on stable demand and insurance coverage, which eliminates seasonal dependence. Despite protection via orphan status, the company faces expansion from industry behemoths. Growth prospects are tied to upcoming clinical trial results, while investors have already priced in the financial risks.

This market metric forecasts the aggregate value of the company's resources, calculating total assets in reverse via ROA to identify hidden balance sheet disparities in real time. Analyzing the balance sheet asset indicator allows for the diagnosis of overpayment risks, which is critical for Quoin Pharmaceuticals (QNRX), as its capitalization during the clinical trial phase of drugs for rare dermatoses depends directly on the efficiency of capital management.